Goldman Sachs Group Inc Reata Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$79.22 - $105.37 $5.97 Million - $7.94 Million	75,344 Added 52.76%	218,143 $22.2 Million
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $5.97 Million - $7.94 Million	75,344 Added 52.76%	218,143 $22.2 Million
Q1 2023 May 14, 2024	SELL	$30.85 - $93.17 $4.02 Million - $12.2 Million	-130,419 Reduced 47.73%	142,799 $13 Million
Q1 2023 May 11, 2023	SELL	$30.85 - $93.17 $4.02 Million - $12.2 Million	-130,419 Reduced 47.73%	142,799 $13 Million
Q4 2022 May 14, 2024	SELL	$22.15 - $42.11 $1.65 Million - $3.14 Million	-74,512 Reduced 21.43%	273,218 $10.4 Million
Q4 2022 Feb 13, 2023	SELL	$22.15 - $42.11 $1.65 Million - $3.14 Million	-74,512 Reduced 21.43%	273,218 $10.4 Million
Q3 2022 May 14, 2024	BUY	$19.41 - $36.49 $5.27 Million - $9.91 Million	271,475 Added 356.01%	347,730 $8.74 Million
Q3 2022 Nov 10, 2022	BUY	$19.41 - $36.49 $5.27 Million - $9.91 Million	271,475 Added 356.01%	347,730 $8.74 Million
Q2 2022 May 14, 2024	BUY	$20.71 - $36.5 $1.58 Million - $2.78 Million	76,255 New	76,255 $2.32 Million
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $644,122 - $1.14 Million	-31,102 Reduced 28.97%	76,255 $2.32 Million
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $25.9 Million - $42.6 Million	-1,075,213 Reduced 90.92%	107,357 $3.52 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $25.7 Million - $112 Million	1,005,161 Added 566.58%	1,182,570 $31.2 Million
Q3 2021 Nov 10, 2021	BUY	$100.0 - $143.02 $17.7 Million - $25.4 Million	177,409 New	177,409 $17.8 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.